- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT00004881
Vaccine Therapy in Treating Patients With Advanced Cancer
Phase I Bridging Trial of TG4010 as Antigen-Specific Immunotherapy in Patients With MUC-1 Positive Advanced Cancer
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells.
PURPOSE: Phase I trial to study the effectiveness of vaccine therapy in treating patients who have advanced cancer.
Studieöversikt
Status
Intervention / Behandling
Detaljerad beskrivning
OBJECTIVES: I. Determine the safety, tolerance, and maximum tolerated dose of TG4010 in patients with MUC1 positive advanced cancer. II. Determine the biological and immunological effects of this regimen in this patient population.
OUTLINE: This is a dose escalation study. Patients receive TG4010 IM weekly for 4 weeks, every other week for 8 weeks, and then every 4 weeks. Treatment continues every 4 weeks in the absence of unacceptable toxicity or disease progression. Cohorts of 3-6 patients receive escalating doses of TG4010 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 3 of 6 patients experience treatment related grade 3 toxicity. If any patient experiences grade 4 toxicity, the prior dose level is considered the MTD.
PROJECTED ACCRUAL: A total of 10 patients will be accrued for this study within 4 months.
Studietyp
Fas
- Fas 1
Kontakter och platser
Studieorter
-
-
California
-
Los Angeles, California, Förenta staterna, 90095-1781
- Jonsson Comprehensive Cancer Center, UCLA
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
DISEASE CHARACTERISTICS: Histologically confirmed cancer not amenable to cure by any standard modality and not suitable for accepted palliative care with chemotherapy, immunotherapy, or hormonal therapy Histologically confirmed MUC1 antigen expression No uncontrolled or symptomatic CNS metastases
PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-2 Life expectancy: At least 3 months Hematopoietic: Hemoglobin at least 9.0 g/dL WBC at least 3,000/mm3 Platelet count at least 100,000/mm3 Hepatic: Bilirubin no greater than 2 times upper limit of normal (ULN) Transaminase no greater than 3 times ULN (unless attributable to metastatic disease) Renal: Creatinine no greater than 2 times ULN Other: Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception during and for 3 months after study HIV negative No active systemic infections No other serious concurrent systemic medical disorders that would preclude study compliance No history of, or immediate household contact with, eczema, exfoliative skin disorders, pregnant women, children under 3 years of age, or other immunocompromise offering an increased risk for disseminated vaccinia infection
PRIOR CONCURRENT THERAPY: Biologic therapy: See Disease Characteristics Chemotherapy: See Disease Characteristics At least 3 weeks since prior chemotherapy (6 weeks for nitrosamines and mitomycin) No concurrent chemotherapy Endocrine therapy: See Disease Characteristics No concurrent systemic corticosteroid therapy No concurrent hormonal therapy Radiotherapy: See Disease Characteristics At least 3 weeks since prior radiotherapy No concurrent radiotherapy Surgery: See Disease Characteristics Other: No concurrent immunosuppressive drugs No other concurrent experimental protocol No other concurrent antitumor therapy
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
Samarbetspartners och utredare
Samarbetspartners
Studieavstämningsdatum
Studera stora datum
Studiestart
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Uppskatta)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Andra studie-ID-nummer
- TRANSGENE-TG4010.01
- UCLA-9909055-01B
- CDR0000067544 (Registeridentifierare: PDQ (Physician Data Query))
- NCI-G00-1677
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på MVA-MUC1-IL2 vaccine
-
TransgeneUniversity of California, Los Angeles; The Cleveland Clinic; University of...AvslutadProstatiska neoplasmerFörenta staterna
-
TransgeneAvslutadKarcinom, icke-småcellig lungaFrankrike, Tyskland, Ungern, Polen
-
Karen KellyBristol-Myers Squibb; National Cancer Institute (NCI); TransgeneAvslutadSteg IIIA icke-småcellig lungcancer | Steg IIIB Icke-småcellig lungcancer | Återkommande icke-småcelligt lungkarcinom | Steg IV icke-småcellig lungcancer | Steg I icke-småcellig lungcancer | Steg II icke-småcellig lungcancerFörenta staterna
-
Memorial Sloan Kettering Cancer CenterNational Cancer Institute (NCI)Avslutad
-
Memorial Sloan Kettering Cancer CenterNational Cancer Institute (NCI)Avslutad
-
Cancer Research UKAvslutadNasofaryngeal cancer | Epstein Barr-virusinfektionerStorbritannien
-
National Institute of Allergy and Infectious Diseases...Indragen
-
University of OxfordAvslutad
-
Memorial Sloan Kettering Cancer CenterNational Cancer Institute (NCI)AvslutadÄggstockscancer | Äggledarcancer | Primär peritonealcancerFörenta staterna
-
University of OxfordMedical Research Council; Ifakara Health InstituteAvslutadMalaria, FalciparumTanzania